COPD Foundation, Inc.

Consolidated Financial Statements
Years Ended June 30, 2016 and 2015

The report accompanying these financial statements was issued by BDO USA, LLP, a Delaware limited liability partnership and the U.S. member of BDO International Limited, a UK company limited by guarantee.

COPD Foundation, Inc.

Contents

Independent Auditor's Report	3
Consolidated Statements of Financial Position	
Consolidated Statements of Activities and Changes in Net Assets	5
Consolidated Statements of Functional Expenses	7
Consolidated Statements of Cash Flows	9
Summary of Significant Accounting Policies	10
Notes to Consolidated Financial Statements	15
Supplemental Information	19

Tel: 305-381-8000
Fax: 305-374-1135
www.bdo.com

1111 Brickell Avenue, Suite 2801
Sabadell Financial Center
Miami, FL 33131

Independent Auditor's Report

Board of Directors
COPD Foundation, Inc.
Coral Gables, Florida

We have audited the accompanying consolidated financial statements of COPD Foundation, Inc. and its subsidiary, which comprise the consolidated statements of financial position as of June 30, 2016 and 2015, and the related consolidated statements of activities and change in net assets, functional expenses, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

BDO USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

BDO is the brand name for the BDO network and for each of the BDO Member Firms.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of COPD Foundation, Inc. and its subsidiary as of June 30, 2016 and 2015, and the changes in its net assets, and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Independent Auditor's Report on Supplementary Information

Our audits were conducted for the purpose of forming an opinion on those statements as a whole. The supplementary information is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audits of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

BDO USA, LLP

September 29, 2016 Certified Public Accountants

BDO USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

BDO is the brand name for the BDO network and for each of the BDO Member Firms.

COPD Foundation, Inc.

Consolidated Statements of Financial Position

June 30,	**2016**	2015
Assets		
Current Assets		
Cash and cash equivalents (includes $1,444 and $1,727 at June 30, 2016 and 2015, respectively, which has been temporarily restricted by the donor)	**$ 2,767,799**	$ 1,960,533
Investment securities (Note 1)	**2,265,488**	1,859,515
Accounts receivable, net – current (Note 2)	**1,770,163**	1,331,612
Prepaid expenses	**88,424**	27,207
Total current assets	**6,891,874**	5,178,867
Investment securities - non-current (Note 1)	**620,126**	703,260
Accounts receivable, net - non-current (Note 2)	**361,299**	1,023,623
Property and equipment, net (Note 3)	**8,518**	7,296
Total assets	**$ 7,881,817**	$ 6,913,046
Liabilities and Net Assets		
Current Liabilities		
Accounts payable and accrued expenses	**$ 730,905**	$ 607,828
Deferred revenue (Note 4)	**2,671,766**	2,037,614
Total current liabilities	**3,402,671**	2,645,442
Commitments and Contingencies (Note 4)		
Net Assets		
Unrestricted	**(1,145,543)**	(461,679)
Temporarily restricted (Note 5)	**5,624,689**	4,729,283
Total net assets	**4,479,146**	4,267,604
Total liabilities and net assets	**$ 7,881,817**	$ 6,913,046

See accompanying summary of significant accounting policies and notes to consolidated financial statements.

COPD Foundation, Inc.

Consolidated Statements of Activities and Changes in Net Assets

Years ended June 30,		**2016**		2015
Changes in Unrestricted Net Assets				
Unrestricted Support and Revenue				
Contributions, bequests and grant revenues	**$**	**4,263,901**	$	4,712,088
Investment and interest income, net		**173,611**		(25,653)
Publications, special events, and other income		**732,511**		870,304
Net assets released from restrictions – satisfaction of program restrictions (Note 5)		**2,340,663**		2,464,634
Total unrestricted support and revenue		**7,510,686**		8,021,373
Unrestricted Expenses				
COPD360		**1,545,076**		535,007
COPD Educational Programs		**1,058,689**		1,445,206
COPD PCORI		**921,534**		861,078
COPD Biomarkers Qualification Consortium		**549,932**		477,938
COPD Research Network		**530,984**		326,513
COPD Publications		**512,708**		467,627
COPD Public Policy		**333,436**		705,724
COPD Gene Study		**306,233**		992,278
COPD Information Line		**224,118**		202,508
COPD Mobile Spirometry Unit		**34,282**		47,048
Respiratory Logistics		**1,385**		915
DRIVE4COPD		**-**		337,165
Total program services		**6,018,377**		6,399,007
Supporting services				
Administration and general		**721,132**		714,637
Fund raising		**1,455,041**		823,765
Total supporting services		**2,176,173**		1,538,402
Total unrestricted expenses		**8,194,550**		7,937,409
(Decrease) Increase in unrestricted net assets		**(683,864)**		83,964
Changes in Temporarily Restricted Net Assets				
Contributions, bequests and grant revenues		**3,236,069**		4,428,773
Net assets released from restrictions (Note 5)		**(2,340,663)**		(2,464,634)
Increase in temporarily restricted net assets		**895,406**		1,964,139
Increase in net assets		**211,542**		2,048,103
Net assets, beginning of year		**4,267,604**		2,219,501
Net assets, end of year	**$**	**4,479,146**	$	4,267,604

See accompanying summary of significant accounting policies and notes to consolidated financial statements.

COPD Foundation, Inc.

Consolidated Statement of Functional Expenses for the Year Ended June 30, 2016

	COPD360	COPD Educational Programs	PCORI	COPD Biomarkers Qualification Consortium	COPD Research Programs	COPD Publications	COPD Public Policy	COPD Gene Study	COPD Information Line	Mobile Spirometry Program	Respiratory Logistics	Total Program Services	Administrative and General	Fund Raising	Year ended June 30, 2016 Total
Awards and grants	$ 114,775	$ 135,452	$ -	$ -	$ 220,212	$ -	$ -	$ -	$ -	$ -	$ -	$ 470,439	$ -	$ -	$ 470,439
Management fees	-	-	-	-	-	-	-	-	-	-	-	-	112,500	-	112,500
Salaries	246,391	247,325	300,008	19,270	46,193	29,717	156,167	49,425	1,375	11,605	-	1,107,476	165,441	512,686	1,785,603
Payroll taxes	16,218	17,665	21,783	1,489	3,410	2,089	11,295	3,720	106	828	-	78,603	10,743	32,604	121,950
Employee benefits	36,183	35,067	51,177	2,221	7,386	5,196	23,929	8,279	166	2,760	-	172,364	27,281	80,723	280,368
Contract services	1,020,567	384,959	418,597	438,967	201,911	219,759	65,160	139,659	207,850	251	-	3,097,680	30,125	448,637	3,576,442
Professional fees	26,053	5,346	15,533	12,915	10,736	2,093	262	-	-	-	40	72,978	59,677	14,369	147,024
Supplies	5,314	8,951	4,280	979	20	555	1,101	2,475	-	2,922	-	26,597	14,683	17,808	59,088
Telephones	4,134	10,037	1,293	292	430	-	2,100	1,345	6,094	-	-	25,725	16,908	2,884	45,517
Online services	1,508	45,078	23,418	2,659	1,401	900	1,480	-	8,527	827	-	85,798	29,597	9,161	124,556
Postage and shipping	941	19,896	17,623	754	832	103,254	1,398	369	-	673	-	145,740	2,757	3,907	152,404
Occupancy	-	-	-	-	-	-	-	-	-	-	-	-	129,502	-	129,502
Equipment repair and	-	-	-	-	-	-	-	-	-	-	-	-			-
maintenance	-	-	-	-	-	-	-	-	-	-	-	-	5,833	8,149	13,982
Printing and publication	497	110,157	14,169	885	86	141,425	1,863	-	-	254	-	269,336	2,287	5,739	277,362
Travel	43,668	33,558	10,323	39,422	10,201	4,887	49,042	100,911	-	8,090	-	300,102	39,989	175,124	515,215
Conferences and meetings	4,327	4,350	3,330	20,480	3,666	2,519	8,084	50	-	6,072	-	52,878	7,733	28,585	89,196
Dues and subscriptions	-	829	-	-	-	314	11,555	-	-	-	-	12,698	8,047	2,989	23,734
Licenses and fees	24,500	19	40,000	9,599	24,500	-	-	-	-	-	1,345	99,963	23,709	23,441	147,113
Utilities	-	-	-	-	-	-	-	-	-	-	-	-	1,566	-	1,566
Insurance	-	-	-	-	-	-	-	-	-	-	-	-	28,160	-	28,160
Special events	-	-	-	-	-	-	-	-	-	-	-	-	-	88,235	88,235
Total expenses before depreciation	1,545,076	1,058,689	921,534	549,932	530,984	512,708	333,436	306,233	224,118	34,282	1,385	6,018,377	716,538	1,455,041	8,189,956
Depreciation and amortization	-	-	-	-	-	-	-	-	-	-	-	-	4,594	-	4,594
Total expenses	$ 1,545,076	$ 1,058,689	$ 921,534	$ 549,932	$ 530,984	$ 512,708	$ 333,436	$ 306,233	$ 224,118	$ 34,282	$ 1,385	$ 6,018,377	$ 721,132	$ 1,455,041	$ 8,194,550

See accompanying summary of significant accounting policies and notes to consolidated financial statements.

COPD Foundation, Inc.

Consolidated Statement of Functional Expenses for the Year Ended June 30, 2015

	DRIVE4COPD	COPD Educational Programs	COPD Biomarkers Qualification Consortium	COPD Gene Study	COPD Publications	COPD Information Line	COPD Public Policy	COPD Research Programs	PCORI	Mobile Spirometry Program	Respiratory Logistics	Total Program Services	Administrative and General	Fund Raising	Year ended June 30, 2015 Total
Awards and grants	$ -	$ -	$ 27,694	$ 339,396	$ -	$ -	$ -	$ 86,046	$ -	$ -	$ -	$ 453,136	$ -	$ -	$ 453,136
Management fees (Note 6)	-	-	-	-	-	-	-	-	-	-	-	-	112,500	-	112,500
Salaries	165,741	228,536	11,119	44,013	14,654	5,560	207,186	151,854	207,638	17,827	-	1,054,128	170,567	309,776	1,534,471
Payroll taxes	9,928	17,171	851	3,358	1,100	425	14,912	11,221	15,314	1,250	-	75,530	13,988	21,557	111,075
Employee benefits	21,637	31,730	1,252	7,965	3,108	626	29,847	23,002	36,406	3,314	-	158,887	24,751	42,121	225,759
Contract services	111,699	708,929	403,966	414,165	209,866	191,356	355,595	530,401	491,798	351	-	3,418,126	43,470	120,119	3,581,715
Professional fees	-	17,278	175	218	3,148	-	1,932	15,673	15,078	-	-	53,502	47,670	5,704	106,876
Supplies	444	12,997	-	158	521	-	3,283	415	7,539	1,680	915	27,952	14,318	7,473	49,743
Telephones	782	9,018	210	1,973	-	4,127	3,631	1,920	395	871	-	22,927	14,256	1,729	38,912
Online services	60	28,822	2,366	-	714	89	9,641	1,260	458	-	-	43,410	24,293	2,135	69,838
Postage and shipping	2,511	40,276	207	318	104,416	-	3,875	250	19,173	2,800	-	173,826	2,558	2,861	179,245
Occupancy	22,620	-	-	-	-	-	-	-	-	200	-	22,820	113,451	-	136,271
Equipment repair and maintenance	-	-	-	-	-	-	-	-	-	-	-	-	6,083	7,583	13,666
Printing and publication	-	112,642	-	-	123,948	-	539	1,013	51,092	-	-	289,234	1,451	3,719	294,404
Travel	1,545	161,907	17,332	172,547	4,714	325	51,598	33,206	12,780	10,783	-	466,737	53,887	116,915	637,539
Conferences and meetings	-	69,264	12,766	8,167	1,163	-	4,032	5,259	3,407	7,893	-	111,951	755	22,651	135,357
Dues and subscriptions	198	6,636	-	-	275	-	19,653	-	-	79	-	26,841	7,494	3,168	37,503
Licenses and fees	-	-	-	-	-	-	-	-	-	-	-	-	24,979	25,029	50,008
Utilities	-	-	-	-	-	-	-	-	-	-	-	-	2,147	-	2,147
Insurance	-	-	-	-	-	-	-	-	-	-	-	-	29,526	295	29,821
Special events	-	-	-	-	-	-	-	-	-	-	-	-	-	130,930	130,930
Total expenses before depreciation	337,165	1,445,206	477,938	992,278	467,627	202,508	705,724	861,520	861,078	47,048	915	6,399,007	708,144	823,765	7,930,916
Depreciation and amortization	-	-	-	-	-	-	-	-	-	-	-	-	6,493	-	6,493
Total expenses	$ 337,165	$ 1,445,206	$ 477,938	$ 992,278	$ 467,627	$ 202,508	$ 705,724	$ 861,520	$ 861,078	$ 47,048	$ 915	$ 6,399,007	$ 714,637	$ 823,765	$ 7,937,409

See accompanying summary of significant accounting policies and notes to consolidated financial statements.

COPD Foundation, Inc.

Consolidated Statements of Cash Flows

Years ended June 30,	**2016**	2015
Operating Activities		
Increase in net assets	**$ 211,542**	$ 2,048,103
Adjustments to reconcile increase in net assets to net cash provided by operating activities:		
Depreciation	**4,594**	6,493
Net realized/unrealized (gain) loss on investments	**(173,611)**	25,653
Donated shares	**-**	(112,055)
Changes in operating assets and liabilities:		
Decrease (increase) in accounts receivable	**223,773**	(1,457,777)
(Increase) in prepaid expenses	**(61,217)**	(2,862)
Increase (decrease) in accounts payable and accrued expenses	**123,077**	(594,936)
Increase in deferred revenue	**634,152**	1,993,614
Net cash provided by operating activities	**962,310**	1,906,233
Investing Activities		
Purchase of Investment securities	**(820,244)**	(1,316,723)
Redemption of Investment securities	**671,016**	515,402
Purchase of property and equipment	**(5,816)**	(1,978)
Net cash (used in) investing activities	**(155,044)**	(803,299)
Net increase in cash	**807,266**	1,102,934
Cash and cash equivalent, at beginning of year	**1,960,533**	857,599
Cash and cash equivalent, at end of year	**$ 2,767,799**	$ 1,960,533

See accompanying summary of significant accounting policies and notes to consolidated financial statements.

COPD Foundation, Inc.

Summary of Significant Accounting Policies

Foundation and principles of consolidation

COPD Foundation, Inc. ("COPD Foundation") was incorporated as a not-for-profit organization under the laws of the State of Florida in 2004. The mission of the COPD Foundation is to support charitable, educational and scientific programs, and to identify and serve persons throughout the United States whose lives are impacted by a diagnosis of chronic obstructive pulmonary disease ("COPD"), which includes those with Alpha-1.

Respiratory Logistics, Inc. ("RLI") is a for-profit entity incorporated under the laws of the State of Delaware in 2009. RLI's mission is to develop and manage commercial activities that are consistent with the overall goals and objectives of the COPD Foundation and to generate recurring sources of revenue to support the activities of the COPD Foundation. COPD Foundation is the sole shareholder of Respiratory Logistics, Inc. Accordingly, the two entities, collectively referred to as the "Foundation", have been consolidated herein. All significant inter-company transactions have been eliminated in consolidation.

Basis of Accounting and Presentation

The financial statements have been prepared on the accrual basis of accounting. Classification of the Foundation's net assets, revenues and expenses are based on the existence or absence of donor-imposed restrictions. The Foundation classifies net assets by the following categories:

- **Unrestricted** – Net assets which are free of donor-imposed restrictions; all revenues, expenses, gains, and losses that are not changes in permanently or temporarily restricted net assets.

- **Temporarily Restricted** – Net assets whose use by the Foundation is limited by donor-imposed stipulations that either expire by passage of time or that can be fulfilled or removed by actions of the Foundation pursuant to those stipulations. The Foundation had temporarily restricted net assets of $5,624,689 and $4,729,283 as of June 30, 2016 and 2015, respectively.

- **Permanently Restricted** – Net assets whose use by the Foundation is limited by donor-imposed stipulations that neither expire with the passage of time nor can be fulfilled or otherwise removed by actions of the Foundation. The Foundation did not have any permanently restricted net assets as of June 30, 2016 and 2015.

Cash and Cash Equivalents

Cash and cash equivalents include all highly liquid investments with maturities of three months or less when purchased.

Investment securities

Investments in securities with readily determinable fair values and investments in debt securities are carried at their estimated fair values in the consolidated statements of financial position. Realized and unrealized gains and losses are included in the change in net assets in the accompanying consolidated statements of activities and changes in net assets.

Accounts Receivable

Accounts receivable represent pledges receivable and other miscellaneous receivables. Management periodically performs a review of its accounts receivable balances to determine if they are impaired based on factors affecting the collectability of those balances. Management's estimate of collectability of these receivables requires management to exercise significant judgment about the timing, frequency and severity of collection losses, if any, which may affect recoverability of such receivables. Management believes that no allowances were required as of June 30, 2016 and 2015 respectively.

Property and Equipment

Property and equipment are recorded at cost or, if donated, at estimated fair market value at the date of donation. Depreciation is provided on the straight-line basis over the estimated useful lives of the assets, ranging from five to seven years.

Fundraising

Revenues from special fundraising events, and the related expenses incurred in generating such revenues are included in "Publications, special events, and other income" and "Unrestricted expenses – Fundraising," respectively in the accompanying June 30, 2016 and 2015 statements of activities and changes in net assets.

During the year ended June 30, 2016, the following fundraising special events were sponsored by the Foundation:

	Revenues	Direct Expenses	Net
COPD Awards Benefit Reception	**$ 158,525**	**$ (88,235)**	**$ 70,290**
	$ 158,525	**$ (88,235)**	**$ 70,290**

During the year ended June 30, 2015, the following fundraising special events were sponsored by the Foundation:

	Revenues	Direct Expenses	Net
COPD Awards Benefit Reception	$ **331,778**	$**(130,930**)	$ **200,848**
	$ **331,778**	$**(130,930**)	$ **200,848**

Income Taxes

COPD Foundation is exempt from Federal income taxes under Section 501 (c)(3) of the Internal Revenue Code. Accordingly, the financial statements do not include an income tax provision, except for certain taxable transactions. During the years ended June 30, 2016 and 2015, COPD Foundation did not have taxable transactions.

The Foundation adopted the provisions of Financial Accounting Standards Board ("FASB") Accounting Standard Codification ("ASC") No. 740 *Income Taxes*. Under ASC 740, the Foundation must recognize the tax benefit associated with tax positions taken for tax return purposes when it is more-likely-than-not that the position will be sustained. The adoption of ASC 740 had no impact on the Foundation's consolidated financial statements. Management of the Foundation does not believe there are any material uncertain tax positions and accordingly has not recognized any liability for unrecognized tax benefits. The Foundation has filed for and received income tax exemptions in the jurisdictions where it is required to do so. Additionally, the Foundation has filed Internal Revenue Service Form 990 tax returns as required and all other applicable returns in those jurisdictions where it is required. The Foundation believes that it is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2013. However, the Foundation is still open to examination by taxing authorities from fiscal year 2013 forward. For the year ended June 30, 2016, there was no interest or tax penalties recorded or included in the statements of activities and changes in net assets.

RLI is a for-profit entity which pays federal income tax. For the years ended June 30, 2016 and 2015, RLI recorded a net loss of $1,385 and $915, respectively. Deferred taxes are not material to the consolidated financial statements and due to the relatively early stages of the operations with no proven earnings history, a full valuation allowance was recorded against such assets.

Allocation of Functional Expenses

Identifiable expenditures made in direct fulfillment of the Foundation's expressed goals are classified as program services. The costs of providing the various programs and other activities have been summarized on a functional basis in the accompanying consolidated statements of functional expenses. Certain common expenses have been allocated among the programs and supporting services based upon management's estimate including factors such as time spent or space utilized.

Volunteer Services

The Foundation utilizes the services of volunteers in their fundraising campaigns. Because there is no objective means of valuing such services, no amounts for such services are recorded in the accompanying consolidated financial statements.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Concentration of Credit Risk

Financial instruments, which potentially subject the Foundation to significant concentrations of credit risk, consist principally of cash and cash equivalents, and Investment securities. As of June 30, 2016 and 2015 the Foundation had cash and cash equivalent in excess of federally insured limits of $2,539,992 and $1,615,155.

The Foundation invests in a variety of publicly traded investment vehicles, including corporate debt and equity securities totaling $2,885,614 and $2,562,775 as of June 30, 2016 and 2015, respectively. Management seeks to mitigate risks inherent in the Foundation's investment portfolio by investing primarily in highly-rated financial instruments and through regular monitoring of the Foundation's investment portfolio.

Fair Value Measurements

The Foundation adopted the provisions of ASC Topic 820 *Fair Value Measurements*, related to financial assets and financial liabilities.

ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market, or if none exists, the most advantageous market, for the specific asset or liability at the measurement date (the exit price). The fair value should be based on assumptions that market participants would use when pricing the asset or liability. ASC Topic 820 establishes a fair value hierarchy that prioritizes the information used in measuring fair value as follows:

Level 1 Inputs include unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.

Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 Inputs that are significant to the measurement that are not observable in the market and include management's judgments about the assumptions market participants would use in pricing the asset or liability (including assumptions about risk).

The Foundation measures fair value as an exit price using the procedures described below for all assets and liabilities measured at fair value. When available, the Foundation uses unadjusted quoted market prices to measure fair value and classifies such items within Level 1. If quoted market prices were not available, fair value would be based upon internally or third party developed models that use, where possible, current market-based or independently-sourced market parameters such as interest rates and currency rates. Items valued using internally generated models would be classified according to the lowest level input or value driver that is significant to the valuation.

The Foundation's Investment securities are valued using Level 1 inputs at June 30, 2016 and 2015.

Subsequent Events

The date to which events occurring after June 30, 2016, the date of the most recent statement of financial position, has been evaluated for possible adjustment to the financial statements or disclosure is September 29, 2016.

1. Investment securities

At June 30, 2016 and 2015, Investment securities consisted primarily of corporate equity and debt securities. Net unrealized gain (loss) on the Foundation's investment portfolio for the years ended June 30, 2016 and 2015, was $139,011 and ($68,930), respectively.

Investments consist of the following at June 30:

	2016	2015
Corporate equity securities	**$ 1,762,457**	$ 1,859,515
Corporate debt securities	**1,123,157**	703,260
Total investments	**2,885,614**	2,562,775
Current	**(2,265,488)**	(1,859,515)
Non-current	**$ 620,126**	$ 703,260

The following summarizes the contractual scheduled maturities of the Foundation's investments in corporate debt securities at face value:

Year ended June 30,	***Amount***
2017	**$ 500,000**
2018	**200,000**
2026	**400,000**
	$ 1,100,000

As of June 30, 2016, yields on the Foundation's corporate debt securities investments maturing through the year 2026 ranged from approximately 1.00% to 3.75%.

2. Accounts Receivable

Accounts receivable represents pledges receivable and other miscellaneous receivables. Pledge receivables that are unconditional promises to give that represent a period of more than one year are measured at present value of future cash flows based on a discount rate of 2% at June 30, 2016 and 2015.

As of June 30, 2016 and 2015, outstanding accounts receivable are as follows:

	Program	2016	2015
Pledges receivable			
Grifols	Unrestricted	**$ 300,000**	$ 150,000
University of Illinois	PCORI	**61,738**	119,540
AstraZeneca	COPD Gene Study	**233,200**	343,000
Medimmune, LLC	COPD Gene Study	**66,800**	167,000
Novartis	COPD Gene Study	**400,000**	800,000
Sunovion	COPD Gene Study	**100,000**	-
Boehringer Ingelheim	COPD Gene Study	**100,000**	-
GlaxoSmithKline	COPD Gene Study	**100,000**	-
Kellen Foundation	Research Net	**443,534**	568,534
PCORI	PCORI	**196,116**	99,708
Subtotal		**2,001,388**	2,247,782
Less: Discount		**(15,236)**	(27,645)
Total pledges receivable		**1,986,152**	2,220,137
Other receivables			
GlaxoSmithKline		**25,000**	-
Medical Dynamics		**-**	29,322
Others		**120,310**	105,775
Subtotal		**145,310**	135,097
Total accounts receivable		**2,131,462**	2,355,234
Less: Noncurrent (over 1 year)		**(361,299)**	(1,023,622)
Current		**$ 1,770,163**	$ 1,331,612

3. Property and Equipment

Property and equipment consists of the following at June 30:

	2016	2015
Furniture and equipment	**$ 68,654**	$ 64,180
Less: Accumulated depreciation	**(60,136)**	(56,884)
	$ 8,518	$ 7,296

4. Commitments and Contingencies

Healthcare Legislation

Certain healthcare-related legislation has been approved and legislation is expected to continue to be introduced in the U.S. Congress and the State of Florida Legislature. Such legislation may address, among other things, benefits provided, insurance coverage and provider reimbursement. It is possible that such legislation could result in a reduction in Medicare and Medicaid spending over the next several years.

At this time, it is not possible to determine the impact, on the Foundation, of any national or state healthcare-related legislation that might be enacted. However, any spending reductions in healthcare coverage or services would likely have an adverse impact on operating results and cash flows. Should such spending reductions be imposed, management believes it can make changes to the Foundation's cost structures to reduce the adverse impact. However, there is no assurance that such changes will be sufficient.

Grant Commitment

In December 2012, COPD Foundation entered into an agreement with the Alpha-1 Foundation where it commits to award a minimum of $500,000 in research grants for research related to Alpha-1 Antitrypsin Deficiency, within six years following the date of the agreement.

On December 14, 2014, the Foundation entered into a contribution agreement with AstraZeneca Pharmaceuticals where the latter as a founding sponsor of COPD 360 registry initiative contributed $2.5 million to be applied for four full years of sponsorship. As founding sponsor, AstraZeneca will have registry access and will also grant certain data query rights throughout the life cycle of the registry. The contributed funds may only be used solely to offset budgeted program expenses of the COPD 360 program. The agreement can be terminated by either party and any unobligated funds will be returned to AstraZeneca within 60 days. As of June 30, 2016 and 2015, the unspent funds of $1,067,459 and $1,992,115 were reported as deferred revenue in the accompanying consolidated statement of financial position.

Operating Leases

Future minimum annual commitments under an operating lease agreement to rent office space, are as follows:

Year ended June 30,		*Amount*
2017	**$**	**95,138**
Total lease commitments	**$**	**95,138**

For the years ended June 30, 2016 and 2015 COPD Foundation incurred rent expense of $129,502 and $136,271 respectively.

5. Temporarily Restricted Net Assets

Temporarily restricted net assets consist of the following at June 30:

	2016	2015
Research Network	**$ 5,351,965**	$ 4,381,196
Other Services	**272,724**	348,087
Total temporarily restricted net assets	**$ 5,624,689**	$ 4,729,283

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes as follows:

Years ended June 30,	**2016**	2015
Research Network	**$ 1,637,400**	$ 1,479,727
Other Services	**703,263**	984,907
Total restrictions released	**$ 2,340,663**	$ 2,464,634

6. Transactions with Related Parties

Management Agreement

In July 2004, COPD Foundation and Alpha-1 Foundation, a related party, entered into a management agreement with AlphaNet to receive management services from certain AlphaNet employees for an annual fee of $250,000, which would be allocated between the Foundations. This agreement is for a one-year period and automatically renews itself at the end of the current term for additional one-year periods. Management fee allocated and expensed for the years ended June 30, 2016 and 2015 amounted to $112,500. However, Alpha-1 made payments on behalf of COPD for those services and therefore this was recorded as in-kind contribution and expenses in the consolidated statement of activities and changes in net assets.

Service Agreement

During 2012, the Foundation entered into an annual agreement, automatically renewed for successive one year periods, with AlphaNet whereby AlphaNet conducts certain accounting, payroll, and human resources functions, manages information technology and telecommunication system services on behalf of the Foundation. Service fee expense for the years ended June 30, 2016, and 2015, was $41,858 and $60,163, respectively, which is classified as contract services in the consolidated statements of functional expenses.

During the years ended June 30, 2016 and 2015, the Foundation made various unsecured, non-interest bearing, due on demand, advances to related entities. These advances are offset against amount owed to the related entities. In addition, the Foundation receives support services from its related entities on a cost reimbursement basis. As of June 30, 2016 and 2015, due to related entities aggregated to $8,549 and $40,486, respectively and were reported as a component of accounts payable in the accompanying consolidated statements of financial position.

7. Grant Commitments

The Foundation provides resources to different institutions to conduct research related to COPD. The projects include clinical research, screening, detection, education, in order to improve health and a cure for COPD. Awards and grants expense for the years ended June 30, 2016 and 2015 were $470,439 and $453,136, respectively. As of June 30, 2016 and 2015, there was no accrual for future grant commitments.

Supplemental Information

COPD Foundation, Inc.

Statements of Financial Position

June 30,		**2016**		2015
Assets				
Current Assets				
Cash (includes $1,444 and $1,727, respectively, which has been restricted by the donor)	**$**	**2,763,753**	$	1,954,556
Investment securities		**2,265,488**		1,859,515
Accounts receivable, net of allowance for bad debts		**1,770,163**		1,331,612
Other assets		**88,424**		27,207
Total current assets		**6,887,828**		5,172,890
Investment securities – non-current		**620,126**		703,260
Investment in RLI		**250,000**		250,000
Accounts receivable, net of allowance for bad debts		**361,299**		1,023,623
Property, plant & equipment, net		**8,518**		7,296
Total assets	**$**	**8,127,771**	$	7,157,069
Liabilities and Net Assets				
Current Liabilities				
Accounts payable and accrued expenses	**$**	**730,905**	$	607,282
Deferred revenue		**2,671,766**		2,037,614
Total current liabilities		**3,402,671**		2,644,896
Net Assets				
Unrestricted		**(899,589)**		(217,110)
Temporarily restricted		**5,624,689**		4,729,283
Total net assets		**4,725,100**		4,512,173
Total liabilities and net assets	**$**	**8,127,771**	$	7,157,069

See Independent Auditor's Report

COPD Foundation, Inc.

Statement of Activities and Change in Net Assets

Years ended June 30,		**2016**		2015
Changes in Unrestricted Net Assets				
Unrestricted Support and Revenue				
Contributions, bequests and grant revenues	**$**	**4,263,901**	$	4,712,088
Investment and interest income, net		**173,611**		(25,653)
Publications, special events, and other income		**732,511**		870,304
Net assets released from restrictions- satisfaction of program restrictions		**2,340,663**		2,464,634
Total unrestricted support and revenue		**7,510,686**		8,021,373
Unrestricted Expenses				
Program services				
COPD360		**1,545,076**		535,007
COPD Educational Programs		**1,058,689**		1,445,206
COPD PCORI		**921,534**		861,078
COPD Biomarkers Qualification Consortium		**549,932**		477,938
COPD Research Network		**530,984**		326,513
COPD Publications		**512,708**		467,627
COPD Public Policy		**333,436**		705,724
COPD Gene Study		**306,233**		992,278
COPD Information Line		**224,118**		202,508
COPD Mobile Spirometry Unit		**34,282**		47,048
DRIVE4COPD		**-**		337,165
Total program services		**6,016,992**		6,398,092
Supporting Services				
Administration and general		**721,132**		714,637
Fund raising		**1,455,041**		823,765
Total supporting services		**2,176,173**		1,538,402
Total unrestricted expenses		**8,193,165**		7,936,494
(Decrease) increase in unrestricted net assets		**(682,479)**		84,879
Changes in Temporarily Restricted Net Assets				
Contributions, bequests and grant revenues		**3,236,069**		4,428,773
Net assets released from restrictions		**(2,340,663)**		(2,464,634)
Increase in temporarily restricted net assets		**895,406**		1,964,139
Increase in net assets		**212,927**		2,049,018
Net assets, beginning of year		4,512,173		2,463,155
Net assets, end of year	**$**	**4,725,100**	$	4,512,173

See Independent Auditor's Report

COPD Foundation, Inc.

Statement of Functional Expenses for the Year Ended June 30, 2016

	COPD360	COPD Educational Programs	PCORI	COPD Biomarkers Qualification Consortium	COPD Research Programs	COPD Publications	COPD Public Policy	COPD Gene Study	COPD Information Line	Mobile Spirometry Program	Total Program Services	Administrative and General	Fund Raising	Year ended June 30, 2016 Total
Awards and grants	$ 114,775	$ 135,452	$ -	$ -	$ 220,212	$ -	$ -	$ -	$ -	$ -	$ 470,439	$ -	$ -	$ 470,439
Management fees	-	-	-	-	-	-	-	-	-	-	-	112,500	-	112,500
Salaries	246,391	247,325	300,008	19,270	46,193	29,717	156,167	49,425	1,375	11,605	1,107,476	165,441	512,686	1,785,603
Payroll taxes	16,218	17,665	21,783	1,489	3,410	2,089	11,295	3,720	106	828	78,603	10,743	32,604	121,950
Employee benefits	36,183	35,067	51,177	2,221	7,386	5,196	23,929	8,279	166	2,760	172,364	27,281	80,723	280,368
Contract services	1,020,567	384,959	418,597	438,967	201,911	219,759	65,160	139,659	207,850	251	3,097,680	30,125	448,637	3,576,442
Professional fees	26,053	5,346	15,533	12,915	10,736	2,093	262	-	-	-	72,938	59,677	14,369	146,984
Supplies	5,314	8,951	4,280	979	20	555	1,101	2,475	-	2,922	26,597	14,683	17,808	59,088
Telephones	4,134	10,037	1,293	292	430	-	2,100	1,345	6,094	-	25,725	16,908	2,884	45,517
Online services	1,508	45,078	23,418	2,659	1,401	900	1,480	-	8,527	827	85,798	29,597	9,161	124,556
Postage and shipping	941	19,896	17,623	754	832	103,254	1,398	369	-	673	145,740	2,757	3,907	152,404
Occupancy	-	-	-	-	-	-	-	-	-	-	-	129,502	-	129,502
Equipment repair and	-	-	-	-	-	-	-	-	-	-	-			-
maintenance	-	-	-	-	-	-	-	-	-	-	-	5,833	8,149	13,982
Printing and publication	497	110,157	14,169	885	86	141,425	1,863	-	-	254	269,336	2,287	5,739	277,362
Travel	43,668	33,558	10,323	39,422	10,201	4,887	49,042	100,911	-	8,090	300,102	39,989	175,124	515,215
Conferences and meetings	4,327	4,350	3,330	20,480	3,666	2,519	8,084	50	-	6,072	52,878	7,733	28,585	89,196
Dues and subscriptions	-	829	-	-	-	314	11,555	-	-	-	12,698	8,047	2,989	23,734
Licenses and fees	24,500	19	40,000	9,599	24,500	-	-	-	-	-	98,618	23,709	23,441	145,768
Utilities	-	-	-	-	-	-	-	-	-	-	-	1,566	-	1,566
Insurance	-	-	-	-	-	-	-	-	-	-	-	28,160	-	28,160
Special events	-	-	-	-	-	-	-	-	-	-	-	-	88,235	88,235
Total expenses before depreciation	1,545,076	1,058,689	921,534	549,932	530,984	512,708	333,436	306,233	224,118	34,282	6,016,992	716,538	1,455,041	8,188,571
Depreciation and amortization	-	-	-	-	-	-	-	-	-	-	-	4,594	-	4,594
Total expenses	$ 1,545,076	$ 1,058,689	$ 921,534	$ 549,932	$ 530,984	$ 512,708	$ 333,436	$ 306,233	$ 224,118	$ 34,282	$ 6,016,992	$ 721,132	$ 1,455,041	$ 8,193,165

See Independent Auditor's Report

Respiratory Logistics, Inc.

Balance Sheets

June 30,		**2016**		2015
Assets				
Cash and cash equivalents	**$**	**4,046**	$	5,977
Total assets	**$**	**4,046**	$	5,977
Liabilities and Stockholder's Equity				
Current Liabilities				
Accounts payable	**$**	**-**	$	546
Total current liabilities		**-**		546
Stockholder's equity				
Common stock $0.01 par value authorized shares- 100,000 issued and outstanding		**1,000**		1,000
Additional paid in capital		**249,000**		249,000
Accumulated deficit		**(245,954)**		(244,569)
Total stockholder's equity		**4,046**		5,431
Total liabilities and stockholder's equity	**$**	**4,046**	$	5,977

See Independent Auditor's Report

Respiratory Logistics, Inc.

Statements of Operations

Years ended June 30,		**2016**		2015
Revenues	**$**	**-**	$	-
Expenses				
Office expenses		**1,385**		915
Net loss	**$**	**(1,385)**	$	(915)

See Independent Auditor's Report